Leach, M. O., Brindle, K. M., Evelhoch, J. L., Griffiths, J. R., Horsman, M. R., Jackson, A., Jayson, G. C., Judson, I. R., Knopp, M. V., Maxwell, R. J., McIntyre, D., Padhani, A. R., Price, P., Rathbone, R., Rustin, G. J., Tofts, P. S., Tozer, G. M., Vennart, W., Waterton, J. C., Williams, S. R. and Workman, P. (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. British Journal of Cancer, 92 (9). pp. 1599-610. ISSN 0007-0920Full text not available from this repository.
Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.
|Keywords:||Angiogenesis Inhibitors/ therapeutic use Antineoplastic Agents/ therapeutic use Clinical Trials Evaluation Studies Magnetic Resonance Imaging Neoplasms/ blood supply/ drug therapy Reproducibility of Results Terminology|
|Schools and Departments:||Brighton and Sussex Medical School > Brighton and Sussex Medical School|
|Depositing User:||Paul Stephen Tofts|
|Date Deposited:||28 Feb 2007|
|Last Modified:||11 Jun 2012 12:37|
|Google Scholar:||234 Citations|